Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620001310954
Ethics application status
Not required
Date submitted
23/07/2020
Date registered
4/12/2020
Date last updated
21/10/2022
Date data sharing statement initially provided
4/12/2020
Date results provided
21/10/2022
Type of registration
Retrospectively registered

Titles & IDs
Public title
Managing Glioblastoma Multiforme with Fasting and a Ketogenic Diet
Scientific title
Managing Glioblastoma Multiforme with Fasting and a Ketogenic Diet: A Case Series
Secondary ID [1] 301868 0
None.
Universal Trial Number (UTN)
U1111-1256-0073
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Glioblastoma 318363 0
Condition category
Condition code
Cancer 316381 316381 0 0
Brain

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
This is a prospective observational study. Patients diagnosed with stage 4 glioblastoma will be informed of the potential benefits and risks of using fasting and a ketogenic diet in glioblastoma. If the patient opts to incorporate this approach into their lifestyle, they will be supported with information and guidance prior to commencing the regimen via a clinical visit at Waikato hospital, followed by weekly emails and, if requested by the patient, video (Zoom) sessions as needed. The recommended regimen will consist of 5-7 days of fasting, alternated with 3 weeks of a ketogenic diet, for a period of up to 2 years post-diagnosis (or more if the patient remains alive, well, and wishes to continue). Observational data (such as MRI scans) will be collected as per the patient's routine care by their treating oncologist, who will be informed of the fasting and ketogenic diet regimen. There will be no further study visits at the hospital other than routine oncology care, unless the situation warrants (such as an unexpected admission for a medical complication of any description).

(1) Materials.
- Fasting materials will include a CareSens blood glucose and ketone monitor (patients will buy).
- Ketogenic diet materials include a diet plan with recipes (on average, per 1,750 kcal per day, the recipes will be composed of 152 g of fat (67 g saturated), 75 g of protein, 16 g net carbohydrate, and 11 g of fiber). This plan is designed by the lead investigator. Patients will also be able to source their own ketogenic diet recipes, although these will be checked by the lead investigator to ensure the fat/carbohydrate/protein ratio conforms to the ratio above.

(2) Procedures.
- Fasting procedure will be a fluid-only fast (water, salt supplementation, black coffee, tea, or bone broth) for 5-7 days in a row. Lemon and lime juice, apple cider vinegar, 1 tsp chia or flax seeds, or a slice of fruit (not to be eaten) may be added to each glass of water. Up to 1 tsp of unsweetened almond milk, cream, coconut oil, butter, MCT oil, or a pinch of cinnamon or nutmeg may be added to coffee, which will be limited to 2-4 cups per day. There will be regular weekly email contact and occasional video sessions (one on the initial fast, more as required later, anticipated to be 20-60 minutes long) to maintain contact with patients and help them surmount any difficulties.
- Ketogenic diet will be as per the diet plan, no limit on the amount of food that may be eaten (ad libitum).
- It is anticipated there will be approximately one fast per month, with all remaining time spent on the ketogenic diet.

(3) Delivery.
- The patient (and partner, if present) will deliver the fasting and ketogenic diet interventions to themselves. The study investigators will only provide guidance and aid in troubleshooting via video throughout. The conversations will be part educational, part question and answer sessions, part support (as any routine clinic visit would be, albeit via video) so as to maximize the chances of success with the diet and fasts. It is anticipated that the sessions will be anywhere from 20-60 minutes in duration. Patients will also be contacted regularly via email to provide encouragement and review any potential problems, email frequency will vary depending on patient need (anticipated to be 1-2 emails a week during the ketogenic diet phase and 3-4 emails a week during the fasts).

(4) Location.
- Fasting and ketogenic diet therapy will largely take place in the patient's own home.

(5) Adherence.
- This will be assessed by monitoring of blood glucose and ketone (beta-hydroxybutyrate) levels, daily during the fasts and three times per week for the ketogenic diet (aiming for a mean glucose to ketone ratio of < 6).
Intervention code [1] 318160 0
Not applicable
Comparator / control treatment
No control group, prospective observational case series only.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 329987 0
Feasibility as determined by glucose to ketone ratio, calculated by dividing the blood glucose level (mmol/L via serum assay) by the beta-hydroxybutyrate (ketone) level (mmol/L via serum assay) to achieve a proportionate value.
Timepoint [1] 329987 0
From day of commencing fasting and ketogenic diet strategy, daily during the fasts and 3 days per week during the ketogenic diet to the date of cessation of either strategy, up to 2 years post-commencement.
Secondary outcome [1] 384929 0
Patient functional status, with Eastern Cooperative Oncology Group (ECOG) performance status scale (completed by lead investigator in a clinic room).
Timepoint [1] 384929 0
On the day of commencing the fasting and ketogenic diet strategy and on the date of cessation of either the fasting or ketogenic diet strategy, up to 2 years post-commencement.
Secondary outcome [2] 384931 0
Weight (kg, measured by lead investigator on a balance scale in clinic room).
Timepoint [2] 384931 0
Weight will be measured twice. Once on the day of commencing the fasting and ketogenic diet strategy, and once again on the date of cessation of the fasting or ketogenic diet strategy, up to 2 years post-commencement..
Secondary outcome [3] 384932 0
MRI tumour features, including volume (cubic cm, assessed by a hospital neuroradiologist blinded to treatment).
Timepoint [3] 384932 0
MRI tumour features will be assessed twice. Once for the most recent MRI done prior to commencement of the fasting and ketogenic diet strategy, and once again on the most recent MRI done prior to cessation of the fasting and ketogenic diet strategy, up to 2 years post-commencement.
Secondary outcome [4] 388239 0
Blood glucose level (mmol/L) via serum assay.
Timepoint [4] 388239 0
From day of commencing fasting and ketogenic diet strategy, daily during the fasts and 3 days per week during the ketogenic diet to the date of cessation of either strategy, up to 2 years post-commencement.
Secondary outcome [5] 388240 0
Blood beta-hydroxybutyrate (ketone) level (mmol/L) via serum assay.
Timepoint [5] 388240 0
From day of commencing fasting and ketogenic diet strategy, daily during the fasts and 3 days per week during the ketogenic diet to the date of cessation of either strategy, up to 2 years post-commencement.
Secondary outcome [6] 404527 0
Safety as measured by a study-specific questionnaire.
Timepoint [6] 404527 0
Safety will be assessed once, on the day of cessation of either the fasting or ketogenic diet strategy, up to 2 years post-commencement.

Eligibility
Key inclusion criteria
(1) Age 18 years or greater.
(2) Histologically confirmed diagnosis of glioblastoma on brain biopsy.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
(1) A medical or psychiatric disorder that would make it difficult to complete the fasting periods or the ketogenic diet.

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Both
Statistical methods / analysis
Only descriptive statistics such as means, medians, standard deviations, and standard errors) will be provided. Kaplan-Meir curves may be presented.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
8/03/2020
Date of last participant enrolment
Anticipated
23/06/2021
Actual
5/12/2020
Date of last data collection
Anticipated
23/06/2023
Actual
7/06/2021
Sample size
Target
10
Accrual to date
Final
10
Recruitment outside Australia
Country [1] 22790 0
New Zealand
State/province [1] 22790 0
Anywhere in New Zealand

Funding & Sponsors
Funding source category [1] 306290 0
Self funded/Unfunded
Name [1] 306290 0
NA
Country [1] 306290 0
Primary sponsor type
Individual
Name
Matthew Phillips
Address
Neurology Dept, Level 1 Reception A, Waikato Hospital, Pembroke St, Hamilton Waikato NZ 3024
Country
New Zealand
Secondary sponsor category [1] 307060 0
None
Name [1] 307060 0
Address [1] 307060 0
Country [1] 307060 0

Ethics approval
Ethics application status
Not required

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 104098 0
Dr Matthew CL Phillips
Address 104098 0
Neurology Dept, Waikato Hospital, Pembroke St, Hamilton NZ 3204
Country 104098 0
New Zealand
Phone 104098 0
+64274057415
Fax 104098 0
Email 104098 0
[email protected]
Contact person for public queries
Name 104099 0
Matthew CL Phillips
Address 104099 0
Neurology Dept, Waikato Hospital, Pembroke St, Hamilton NZ 3204
Country 104099 0
New Zealand
Phone 104099 0
+64274057415
Fax 104099 0
Email 104099 0
[email protected]
Contact person for scientific queries
Name 104100 0
Matthew CL Phillips
Address 104100 0
Neurology Dept, Waikato Hospital, Pembroke St, Hamilton NZ 3204
Country 104100 0
New Zealand
Phone 104100 0
+64274057415
Fax 104100 0
Email 104100 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Potentially any data requested, depends on intended use (but will all be de-identified).
When will data be available (start and end dates)?
Immediately upon (same day of) publication, no end date.
Available to whom?
Medical professionals and researchers.
Available for what types of analyses?
Any statistical analysis.
How or where can data be obtained?
Emailing the corresponding author at [email protected].


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseFeasibility and Safety of a Combined Metabolic Strategy in Glioblastoma Multiforme: A Prospective Case Series.2022https://dx.doi.org/10.1155/2022/4496734
N.B. These documents automatically identified may not have been verified by the study sponsor.